Physician profile
Howard E Sperry
NPI 1235169848
$6,005.49
in general payments reported to CMS, 2019-2025
27 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $709 · 2021: $870 · 2022: $790 · 2023: $740 · 2024: $981 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,819.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,225.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $977.82 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $636.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $574.90 | 2019-2025 | |
| Amgen INC. | $410.37 | 2019-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $406.20 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $283.77 | 2021-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $280.21 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $217.42 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $188.44 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.10 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $96.86 | 2025 | |
| Amarin Pharma, INC. | $91.51 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $68.17 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $47.26 | 2019 | |
| Paratek Pharmaceuticals, INC. | $36.95 | 2025 | Nuzyra, Xhance |
| Astellas Pharma US INC | $30.08 | 2024 | Veozah |
| Daiichi Sankyo INC. | $25.14 | 2023 | Injectafer |
| Sanofi Pasteur INC. | $18.69 | 2020 | |
| Eisai INC. | $18.13 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.10 | 2023 | Quviviq |
| Gilead Sciences, INC. | $17.94 | 2024 | |
| Bausch Health US, LLC | $16.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.71 | 2019 | |
| Allergan, INC. | $12.27 | 2019 | |
| Dynavax Technologies Corporation | $10.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Sperry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.